Loading
Pathologists disagree about faint HER2 staining, yet that decision unlocks Enhertu. Let a validated algorithm do the counting.
Pathologists disagree about faint HER2 staining, yet that call decides who receives trastuzumab deruxtecan, so this idea hands the counting to a validated algorithm. A continuous AI-derived HER2 membrane score is expected to predict T-DXd benefit better than pathologist-assigned IHC categories and to reclassify some IHC 0 tumours as eligible, because benefit depends on a continuous delivery threshold that binned human scoring discards. The test is a retrospective analysis of DESTINY-Breast04 and DESTINY-Breast06 slides with an AI scorer, then prospective companion-diagnostic validation. At early-clinical maturity it addresses the bottlenecks Biomarkers are not validated or standardised and AI that is built but not validated or deployed.
One of the most cited trial reports Europe PMC returns for Trastuzumab deruxtecan in HR-positive / HER2-negative breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for Trastuzumab deruxtecan in Triple-negative breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for Trastuzumab deruxtecan in Triple-negative breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares A standard evaluation pathway for AI-assisted pathology, from reader study to deployment, Version control and locked reference sets for AI algorithms used as companion diagnostics, AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions, AI that is built but not validated or deployed.
Shares DESTINY-Breast04, HER2-low and HER2-ultralow, Digital pathology & AI, Immunohistochemistry (IHC).
Shares A standard evaluation pathway for AI-assisted pathology, from reader study to deployment, Version control and locked reference sets for AI algorithms used as companion diagnostics, AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions, AI that is built but not validated or deployed.
Shares Calibrated reference slides so every lab scores HER2-low the same way, DESTINY-Breast06, HER2-low and HER2-ultralow, Immunohistochemistry (IHC).
Shares DESTINY-Breast04, HER2-low and HER2-ultralow, Digital pathology & AI, Immunohistochemistry (IHC).
Shares DESTINY-Breast06, DESTINY-Breast04, HER2-low and HER2-ultralow, Immunohistochemistry (IHC).
Shares Version control and locked reference sets for AI algorithms used as companion diagnostics, AI that is built but not validated or deployed, Digital pathology & AI, Biomarkers are not validated or standardised.
Shares DESTINY-Breast04, HER2-low and HER2-ultralow, Immunohistochemistry (IHC), Trastuzumab deruxtecan.